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Three types of human lung tumour cell lines can be distinguished
according to surface expression of endogenous urokinase and their
capacity to bind exogenous urokinase
R. Schwartz-Albiezl, H.-H. Heidtmann2, D. Wolf', V. Schirrmacherl & G. Moldenhauerl
'Institute ofImmunology and Genetics, German Cancer Research Center, D-6900 Heidelberg; 2Department ofInternal Medicine,
Division ofHematology/Oncology, Philipps-University, D-3500 Marburg, Germany.
Summary This study evaluates the cell surface expression of urokinase-type plasminogen activator (u-PA)
and the capacity to bind exogenous urokinase as possible parameters for the distinction of various types of
human lung tumours. Twelve different tumour cell lines including four small cell carcinoma, two large cell
carcinoma, three squamous cell carcinoma, one adenocarcinoma and two mesothelioma cell lines of lung
origin were investigated. Surface expression of endogenous u-PA was determined in a cellular radioimmunoas-
say (CRIA) using the u-PA-specific monoclonal antibody 98/6. To estimate additional u-PA binding capacity,
exogenous two-chain, 54 kDa u-PA was employed in the CRIA. The influence of phorbol ester (PMA)
treatment on expression and binding of these molecules was studied. Three different groups of lung tumour
cell lines could be distinguished according to their expression of u-PA and u-PA-binding ability: (i) non small
cell lung carcinoma (NSCLC) cell lines of squamous cell carcinoma/adenocarcinoma origin expressed small
amounts of u-PA and bound little u-PA. Large cell carcinoma cell lines expressed high amounts of u-PA and
bound large amounts of u-PA. In general, expression of u-PA and u-PA binding was enhanced after PMA
treatment. (ii) Mesothelioma cell lines did not express u-PA, but were able to bind u-PA. (iii) Small cell
carcinoma (SCLC) lines were devoid of surface-expressed u-PA and could not bind u-PA, both under
untreated and PMA-treated conditions. It could thus be demonstrated that these three groups of lung tumour
cell lines differ in their ability to express u-PA and to bind external u-PA. This may reflect the different in vivo
growth behaviour and origin of the respective tumour groups.
Based on characteristic histological structures, human lung
tumours can be classified into two major groups: NSCLC
(squamous cell carcinoma, adenocarcinoma, large cell car-
cinoma) and SCLC, SCLC can be distinguished from
NSCLC by their clinical behaviour, the occurrence of metas-
tases at very early stages of tumour development and certain
serological parameters (Gazdar et al., 1981; World Health
Organisation, 1982). The biological mechanisms underlying
the different metastatic behaviour of these tumour groups are
poorly understood.
Since several studies suggested a contribution of plas-
minogen activators (PA) in tumour invasion and in the for-
mation of distant metastases (Dan0 et al., 1986; Ossowski &
Reich, 1983), we investigated the PA-system in human lung
tumour lines in order to better understand the biological
basis of these malignancies and to use this enzyme system as
possible means to differentiate human lung tumours.
PA-mediated proteolysis may cause degradation of struc-
tural constituents of the extracellular matrix (ECM) which
may result in a facilitated intra- and extravasation of tumour
cells during metastasis formation.
For a more comprehensive evaluation of the relationship
between tumour malignancy and PA activity, other com-
ponents of this enzyme system as, for instance, plasminogen
activator inhibitors (PAI) (Cwikel et al., 1984; Eaton &
Baker, 1983; Genton et al., 1987) as well as the micro-
environment, have to be considered. For instance, growth
factors like epidermal growth factor (EGF) and transforming
growth factor-, (TGF-,B) are known to regulate synthesis and
secretion of both proteolytic and inhibitory components of
the PA system (Keski-Oja et al., 1988; Lee & Weinstein,
1978). In a previous study we analysed both PA and PAI in
human lung tumour lines of different origin (Heidtmann et
al., 1989). We found that cell lines of NSCLC origin pro-
duced and secreted PA of u-PA and t-PA type and PAI in
various amounts and combinations. Strikingly, cell lines of
SCLC and mesothelioma origin were not able to produce any
protein of the PA system. NSCLC cell lines generally showed
increased PA activity when treated with EGF and reduced
PA activity and enhanced formation of PA/PAI-complexes
when treated with TGF-P. SCLC cell lines did not respond to
these growth factors (non published data).
PA may not only be effective in tumour-associated deg-
radation processes by a secreted but also by a cell surface-
bound form. Receptors for u-PA have been described for
several cell types, as for instance for monocytes and the
monocytic cell line U937 (Plow et al., 1986; Stoppelli et al.,
1985; Vassalli et al., 1985), the foetal lung fibroblast cell line
GM 1380 (Plow et al., 1986), and the human carcinoma cell
line A431 (Stoppelli et al., 1986). Recently, a 55 kDa glyco-
protein was characterised as an u-PA receptor in cloning and
transfectant studies (Roldan et al., 1990). It may well be that
tumour cells synthesise little or no u-PA, but may have
unoccupied u-PA binding sites which enable them to use
external u-PA for degradation processes.
While the autocrine binding of biosynthetic pro-u-PA to
the u-PA receptor is well established (Stoppelli et al., 1986),
binding mechanisms of exogenous u-PA to epithelial cells
require closer investigation. For example, several studies
indicate an involvement of surface-located proteinase inhibi-
tors, such as PAI-I (Cubellis et al., 1990) and Protease-Nexin
(Baker et al., 1980), in the complexation and processing of
u-PA. In a first attempt to study these questions in human
lung tumours, we determined the presence of cell surface-
expressed u-PA and the capacity to bind exogenous u-PA on
human lung tumour lines of NSCLC, SCLC and mesothe-
lioma origin. We also applied PMA in our investigations,
since it has been shown to be a potent stimulator of the PA
system in various cell types (Eaton & Baker, 1983; Heidt-
mann et al., 1989; Lee & Weinstein, 1978). By measuring
these parameters, three groups of human lung tumour cell
lines could be distinguished.
In addition to synthesis and expression of constituents of
the PA system, u-PA surface binding may represent a fur-
ther component to distinguish mesothelioma cell lines from
NSCLC and SCLC cell lines. SCLC cell lines, although
derived from highly metastatic tumours, were found to be
totally deficient of the PA system. The PA system may play a
role in the metastatic process of NSCLC and, in an indirect
way, mesotheliomas of the lung.
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Materials and methods
Materials
Urokinase 54 kDa (Ukidan, Serono, Freiburg, Germany);
urokinase 33 kDa, plasminogen from human plasma, two-
chain t-PA from human melanoma cell culture, thrombin,
Dowex resin (200-400 mesh size), PMA (Sigma, St. Louis,
MO); BSA (Serva, Heidelberg, Germany); gelatine (Merck,
Darmstadt, Germany); [125I] (16.2 mCiLg-' sodium iodide,
Amersham & Buchler, Braunschweig, Germany); goat anti-
rabbit IgG-peroxidase and goat anti-mouse IgG-peroxidase
(Jackson, Avondale, PA); 3,3'-diamino-benzidine-tetrahydro-
chloride (DAB) (Fluka, Buchs, Switzerland); 0-phenylene-
diamine dihydrochloride (OPD) (Eastman Kodak, Rochester,
N.Y.); nitrocellulose membrane filters (Schleicher & Schuill,
Dassel, Germany); RPMI 1640 culture medium and FCS
(Gibco, Paisley, Scotland); PVC microtiter plates (Dynatech,
Plochingen, Germany); Titertek immuno assay plates (Flow
Laboratory, Meckenheim, Germany); Venimmun (Behring
Werke, Marburg, Germany).
Production and characterisation ofMAb 98/6 against u-PA
For the production of MAb against u-PA, female BALB/c
mice were immunised by subcutaneous injection of 50fg
purified low molecular (33 kDa) u-PA dissolved in 100 ftl
PBS, mixed with the same volume of complete Freund's
adjuvant. The mice were boostered twice at 3 week intervals,
first by subcutaneous injection of the same amount of
antigen mixed with incomplete Freund's adjuvant, followed
by a last intraperitoneal injection of the pure antigen in PBS
3 days prior to the fusion. The fusion was performed as
described previously (Moldenhauer et al., 1987). Specificity of
hybridomas was tested in an ELISA on purified u-PA vs
human t-PA and plasminogen. In brief, proteins were coated
to activated ELISA microtiter plates (Flow) (0.3 iLg in
100IsI 0.05 M sodium carbonate buffer, pH 9.6/well) over-
night at room temperature. After two washing steps with
PBS + 0.05% Tween 20, non-specific binding sites were sat-
urated with PBS + 0.02% gelatine for 4 h at 37C. After
vigorous washing with PBS + 0.05% Tween 20, MAb 98/6
supernatant (100 LIl well) was given to the plates for 1 h at
37°C followed by washing with PBS + 0.05% Tween 20.
Peroxidase-conjugated goat anti-mouse Ig diluted in PBS-
+ 0.05% Tween 20, 100 LlI well was added for a further hour
at 37°C. After four washing steps, the substrate OPD
(1 mg ml-') dissolved in 0.1 M KH2PO4, pH 6.0 and 1 L
H202 (30% v/v stock solution in H20) was added to the
assay. The reaction was stopped by addition of 1 N H2SO4
and the optical density (OD) was measured with an ELISA
reader (Titertek multiskan, Flow) at 492 nm.
Appropriate hybridomas were subcloned by limiting dilu-
tion on a feeder layer of BALB/c spleen cells (5 x 105
cell ml-1). Hybridomas of interest were propagated as ascitis
in syngeneic mice.
As control antibodies we applied MAb HEA 125 recognis-
ing an epithelium-specific surface glycoprotein of 34 kDa
(Moldenhauer et al., 1987; Momburg et al., 1987) and MAb
HD37 recognising the B lymphocyte-specific differentiation
antigen CD19 (Pezzutto et al., 1986).
Cell lines and cell culture conditions
Cell lines EPLC-65H, EPLC-32M1 (Bepler et al., 1988), SK-
LC-LL (Fogh & Trempe, 1975) were of squamous cell origin;
cell line SK-LU-1, supplied by American Type Culture Col-
lection, was of adenocarcinoma origin; cell lines SCLC-21H,
SCLC-22H, SCLC-24H, SCLC-86M1 (Bepler et al., 1987a,b)
were of small cell origin; cell lines LCLC-103H, LCLC-
97TM1 (Bepler et al., 1988) were of large cell origin; cell lines
MSTO-21 1H (Bepler et al., 1988) and CH3LC, established by
Dr C. Hellstr6m and kindly provided by Dr G.J. Hammer-
ling, German Cancer Research Center, were of mesothelioma
origin. Morphological, genetical, biochemical and chromo-
somal characteristics of these cell lines have been described in
the above cited studied. Histology, morphology and charac-
teristic biochemical markers of cell lines established in our
laboratory (H.-H.H.) are listed in Table I. All cell lines were
regularly grown in RPMI 1640 medium supplemented with
5% FCS. For assays, serum supplement was reduced to 1%
FCS. Reduction of FCS content did not change morphology,
proliferation rate and amount of cell-bound u-PA as deter-
mined in preceding experiments. In contrast to SCLC cell
lines, NSCLC and mesothelioma cell lines grew plastic adhe-
rent and were brought into suspension by short treatment
with a 0.2% EDTA (w/v) solution in PBS. SCLC cells grew
in floating clusters. Single cell suspensions were produced by
gently pipetting clusters up and down. All cell lines were
screened for the absence of mycoplasms.
CRIAfor u-PA determination on cell surface
Monoclonal antibodies and u-PA were '251-labelled by the
Chloramine T method (Greenwood et al., 1963). In brief,
100fig of the protein solution in 100ftl PBS were incubated
with 1 mCi of Na 1251 and 50 tlI Chloramin T (1 mg 1 ml -
distilled water) for 1 min at room temperature. Reaction was
stopped by addition of 50 tlI sodium metabisulfite (1 mg
NaS205 1 ml-' distilled water). The reaction mixture was
given immediately over a ion exchange chromatography col-
umn (2 ml volume, Dowex, 200-400 mesh size, counter ion
CI-), Fractions of 500 tlI were sampled and measured for
radioactivity. The peak fraction was used for the cellular
radioimmuno assay (CRIA). The CRIA was performed in
flexible polyvinyl chloride microtiter plates, as described
previously (Schwartz et al., 1985). Plates were blocked for
nonspecific binding by preincubation with PBS + 0.2% (v/v)
gelatine (200 ftl well) at 4°C overnight. After emptying,
1 x 106 viable target cells in 50ttl PBS + 0.2% gelatine and
5% (v/v) pooled human immunoglobulins (Venimmun) were
incubated with 2 x 106c.p.m. of 251I-labelled MAb or 125I1
labelled u-PA in 100yl PBS + 0.2% gelatine + 5% Venim-
mun for 1 h at room temperature. The plates were washed
four times with PBS + 0.2% gelatine by centrifugation and
aspiration of the supernatant. Radioactivity of specifically
cell-bound MAb was determined in a gamma-counter.
The CRIA was applied in three different test systems:
(1) In order to determine endogenous surface expressed
u-PA, '25I-labelled MAb 98/6 was applied as described
above. As controls, radiolabelled MAb HEA 125 and
HD 37 were used.
(2) To determine unoccupied binding sites for u-PA, cell
lines were incubated with '25I-labelled, two-chain u-PA as
described.
(3) For estimation of u-PA binding capacity in case of
mesothelioma cell lines, cells were preincubated with 10ytg
unlabelled, two-chain u-PA/I x 106 cells for 1 h at room
temperature prior to incubation with '25I-labelled MAb
98/6.
In order to test for binding specificity of u-PA, represen-
tative cell lines of squamous cell carcinoma, large cell car-
cinoma, SCLC and mesothelioma were incubated with
2 x 106 c.p.m. of '25I-u-PA in the presence of unlabelled u-PA
in excess (1-10ipg u-PA/I x 106 cells). Addition of 1 ig
unlabelled u-PA abolished binding of 125I-u-PA to back-
ground values in all cell lines. In SCLC cell lines competition
with unlabelled u-PA had no effect on the residual radio-
activity bound. Unrelated proteins such as insulin or throm-
bin added in the same amounts as unlabelled u-PA did not
affect specific binding of 125I-u-PA to the cells.
Estimation of the number of cell surface-expressed u-PA
molecules was done by measuring the binding of 1251-labelled
MAb 98/6 followed by Scatchard plot analysis (Scatchard,
1949).
Western blot analysis and immunochemical staining
After separation of u-PA on SDS-PAGE, both under reduc-
ing and non-reducing conditions, the electrophoretic transferUROKINASE ON HUMAN LUNG TUMOUR CELL LINES 53
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of u-PA to nitrocellulose was performed at 5 V cm-' over-
night at 4°C as described (Towbin et al., 1979). Unspecific
binding sites were blocked by a solution of 2% BSA in PBS
for 1 h at room temperature. Incubation with specific anti-
bodies and second peroxidase-conjugated antibody was
carried out in PBS + 1% BSA, each for 1 h at room tempera-
ture. After every incubation with antibody solutions, the
nitrocellulose was vigorously washed with PBS + 0.05%
NP40. Finally, the binding of antibodies was visualised with
diaminobenzidine (1 mg ml-' in 0.05 M Tris/HCl, pH 7.6)
with 0.01% H202. The staining reaction was stopped by
rinsing the nitrocellulose with 0.05 M Tris/HCl, pH 7.4.
Results
Characterisation ofu-PA specific MAb 98/6
Monoclonal antibody 98/6 specific for u-PA was of IgGi
isotype as determined by an ELISA using subclass-specific
goat anti-mouse Ig antibodies. In Western Blot analysis,
MAb 98/6 reacted with the 54 kDa two chain form and the
33 kDa single chain form of u-PA under non-reducing condi-
tions and with the 33 kDa but not with the 24 kDa chain of
the 54 kDa two chain form under reducing conditions (Fig-
ure 1). In immunoprecipitation of lysates from surface radio-
iodinated cells, MAb 98/6 precipitated a protein which ran in
gel electrophoresis under reducing conditions at approx.
50 kDa (data not shown). Therefore, MAb 98/6 most likely
also recognises the pro-u-PA from. The MAb 98/6 reacted
neither with human t-PA nor with plasminogen as evaluated
by ELISA.
Cell surface expression ofendogenous u-PA on human lung
tumour cell lines
Twelve human lung tumour cell lines of different origin,
histology and growth characteristics (Table I) were studied
for their surface expression of u-PA in a cellular radioim-
c->
x
E
a
94 N
JW- 111S1~~~~~~~~~~~~~~~~~~~~~~
ie
7-
43
3-
b -c d_
_ _ __
_ __ __ _ l__ _
_
= B _ __|_._l.
_ _ __l..__..:
___
_..-.|__s__
|- l-
-: _E
* - *-
S- S- --
---.....:
_
_
_ _
_ _
_ _
.
.
.
e
.
-
-
.
-
.
-
-
-
*f. * e
_
i
*
.
| E
. [
E
|
r
[
i g
.
| |
|
i
W
l
E
|
.
|
i
E
20-
Figure 1 Western blot analysis of MAb 98/6 on purified human
u-PA. Human u-PA (54 kDa, two chain) was separated on 12%
SDS-PAGE prior to transfer to nitrocellulose. PAGE was run
under non-reducing a,c, and reducing conditions b,d,e,f. Specific
staining was performed with MAb 98/6 a,b, and a polyclonal
rabbit anti-u-PA serum (produced by one of the authors, G.M.)
c,d, recognising both chains of u-PA; an irrelevant MAb (HD20)
e, and rabbit pre-immune serum f, were taken as controls.
muno assay (CRIA) using radiolabelled MAb 98/6 specific
for u-PA. (Table II). Three groups of lung tumour cell lines
could be distinguished by this criterion. NSCLC cell lines of
squamous cell/adenocarcinoma origin showed weak reaction
with MAb 98/6 (3-5 fold background binding) which was
increased after PMA treatment. The two large cell carcinoma
cell lines had a much stronger reaction with MAb 98/6 than
squamous cell carcinoma cell lines which could also be
enhanced by PMA.
All SCLC cell lines and the two cell lines of mesothelioma
origin were negative for u-PA surface expression. Binding of
MAb 98/6 in the range of 200-600 c.p.m., which
occasionally occurred in these cell lines, was considered as
unspecific. It was previously shown that these cell lines do
not synthesise u-PA (Heidtmann et al., 1989).
To assess the number of u-PA molecules present on the
surface of viable cells, we performed Scatchard plot analyses.
For example, cell line EPLC 32M I expressed approx
3.6 x 10o u-PA molecules/cell under normal cell culture con-
ditions and approx 1.6 x 105 u-PA molecules/cell after PMA
treatment (Figure 2). As expected from CRIA results, cell
line LCLC 103H expressed more u-PA molecules than the
squamous cell carcinoma cell lines (approx 1.88 x 106 mole-
cules/cell untreated and approx 1.9 x 106 molecules/cell after
treatment with PMA).
The epithelium-specific MAb HEA 125 was applied in the
CRIA as positive control MAb for epithelial cells. This MAb
had previously been shown to react with NSCLC cell lines
and in an even stronger fashion with SCLC cell lines
(Moldenhauer et al., 1987). These results could be affirmed in
the CRIA performed for this study. In all epithelial cell lines
expression of the HEA 125 antigen was unchanged or even
reduced after PMA treatment.
Cell surface binding ofexogenous u-PA to human lung tumour
cell lines
The capacity of the cell lines to bind exogenous, radio-
iodinated two chain (54 kDa) u-PA is given in Table III. In
this CRIA, the presence of unoccupied binding sites for u-PA
was determined. Squamous/adenocarcinoma and large cell
carcinoma cell lines expressed endogenous u-PA at the sur-
face as shown in Table II. Additionally, these cell lines had
free binding capacity for u-PA. Both LCLC cell lines showed
Table II Surface expression of endogenous u-PA on human lung
tumour cell lines with and without PMA treatment
Binding ofradioiodinated MAb98/6
(cpm)
Tumour type Cell line -PMAa + PMA
Squamous EPLC 32 Ml 4,920 + 20b 13,210 + 320
cell EPLC65H 3,010+ 40 11,930± 570
carcinoma SK-LC-LL 1,470 + 60 6,480 + 170
Adeno SK-LU-1 2,110+ 110 6,520 130
carcinoma
Large LCLC 97TM1 63,890 + 2,550 90,920 ± 7,630
LCLC 103H 121,290+ 13,000 163,710 + 2,030
Mesothelioma MSTO 211H 300 260 420 ± 130
CH3LC 0 °
Small cell SCLC 21H 430 ± 320 600 ± 60
carcinoma SCLC 22H 0 0
SCLC 24H 0 320 210
SCLC 86M1 0 230 180
aCells were incubated with and without PMA (5 x 10-9M) for 3 days.
b + standard deviation (s.d.) of triplicates. Non-specific binding was
determined with MAb HD37 (Pezzutto et al., 1986) and was subtracted
from values ofMAb 98/6 binding. As positive control MAb HEA 125,
an epithelium-specific marker, was used (Moldenhauer et al., 1987).
Both mesothelioma cell lines were negative for HEA 125 expression.
The experiment was carried out three times with essentially identical
results. SCLC cell lines and mesothelioma cell lines were regarded as
negative for mAb98/6 binding. These cell lines were shown to be
negative for u-PA synthesis (Heidtmann et al., 1989).UROKINASE ON HUMAN LUNG TUMOUR CELL LINES 55
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Figure 2 Scatchard plot analysis for binding of MAb '25I-98/6 to
EPLC 32 MI cells under untreated a, and PMA-treated condi-
tions b. To 1 x 106 cells, increasing amounts of radiolabelled
MAb 98/6 (from 1 x 105 to 3 x I07 c.p.m.) were added for 1 h at
room temperature.
TableIII Bindingof'251I-labelled u-PAtohuman lungtumourcelllines
with and without PMA treatment
Binding of'251-u-PA (cpm)
Tumour type Cell line -PMAa + PMA
Squamous EPLC 32 M1 13,700+ 410b 18,570 480
cell EPLC 65H 11,880+ 1,520 27,830 350
carcinoma SK-LC-LL 18,390 ± 410 24,000 ± 670
Adeno SK-LU-1 13,510+ 220 17,260 300
carcinoma
Large cell LCLC 97TM1 101,370+ 1,720 71,950+4,930
carcinoma LCL 103H 124,300 + 16,280 60,520 + 3,140
Mesothelioma MSTO 211H 19,330± 1,140 21,800± 580
CH3LC 28,000 ± 1,020 54,830 ± 3,690
Small cell SCLC 21H 2,000+ 1,150 3,100 1,150
carcinoma SCLC 22H 0 2,700 ± 670
SCLC 24H 0 0
SCLC 86M1 0 0
aCells were incubated with and without PMA (5 x 10-9M) for 3 days.
± Standard deviaton (s.d.) of triplicates. Presence of u-PA binding
sites was determined by using '251I-labelled two chain 54 kDa u-PA.
Approximate background values were evaluated by incubating cells
with2 x 106 c.p.m. 251I-u-PAand 1 jLgunlabelled u-PAatthesametime.
These values were subtracted from those of 1251-u-PA binding. This
CRIA was carried out three times with essentially identical results.
a much stronger binding of '25I-u-PA than squamous cell
carcinoma lines. As an exception, binding of external u-PA
was reduced after PMA treatment in these cells. Although
two SCLC cell lines showed low binding values of 251I-u-PA
in the experiment presented in Table III, we regarded all
SCLC cell lines as negative for u-PA binding sites for the
following reasons: (i) in kinetic studies SCLC lines did not
respond with an increased binding of '251-u-PA like the other
cell lines positive for u-PA binding (Figure 3) (ii) competition
experiments with unlabelled u-PA did not result in a concen-
tration-dependent reduction of '251-u-PA binding. In contrast,
cell lines of mesothelioma origin, although deficient to pro-
Incubation time (min)
Figure 3 Kinetics of '251-u-PA binding to human lung tumour
cell lines. Cells were incubated for 3 days untreated or treated
with PMA (5 x 10-9M) prior to the binding assay. Cells were
incubated with u-PA (2 x 106c.p.m.) at room temperature for
various times. EPLC 32 MI untreated (0) and treated (0);
CH3LC untreated (0) and treated (U); SCLC 21H untreated
(A) and treated (A).
duce u-PA (Heidtmann et al., 1989), were able to bind
exogenous u-PA in amounts comparable to those of squa-
mous cell carcinoma lines. Also, PMA enhanced binding of
u-PA in these cells.
In contrast to the findings of other groups, who inves-
tigated the nature of the u-PA receptor, (Plow et al., 1986;
Stoppelli et al., 1986) labelled u-PA could not be replaced by
unlabelled u-PA (applied in the range of 10 gg-0.001 ILg
well) when unlabelled u-PA was added to the cells after
60min incubation with '25I-u-PA. This result was observed
with squamous cell carcinoma and mesothelioma cell lines,
both untreated and treated with PMA. Since binding of u-PA
to the cells was irreversible, it did not seem to be mediated
by the u-PA receptor described earlier (Stoppelli et al., 1985).
We tentatively conclude that surface binding of exogenous,
two-chain u-PA occurs via an irreversible, presumably cova-
lent, complex with a yet unknown surface protein. Further
biochemical characterisation of this complex, which will be
published elsewhere, supports this notion. This irreversible
complex formation may also explain why Scatchard plot
analysis of exogenous '25I-labelled u-PA binding did not
results in a linear function.
In kinetic experiments maximum binding of external u-PA
was achieved after a 60 min incubation period at room
temperature for NSCLC and mesothelioma cell lines (Figure
3).
Estimation ofu-PA binding sites on the surface ofcell line
CH3LC being devoid ofendogenous u-PA
Since cell lines of mesothelioma origin were the only ones
studied here which did not produce u-PA, but were able to
bind exogenous u-PA, we closer examined the capacity of
these cells to bind u-PA. For this purpose, CH3LC cells were
preincubated with unlabelled u-PA (1Ojig/l x 106 cells) for
1 h at room temperature and then '25I-mAb 98/6 was added
in increasing amounts. Scatchard analysis yielded 7.23 x 104
occupied binding sites/cell for untreated cells and 1.96 x 105
occupied binding sites/cell for PMA-treated cells (Figure 4).
Direct measurement of u-PA binding sites by incubation of
cells with various amounts of radiolabelled u-PA did not
result in a reliable linear Scatchard plot.
In competition experiments unlabelled u-PA was simultan-
eously added in increasing amounts to CH3LC cells together
with a constant amount of labelled u-PA. After addition of
0.01 tLg unlabelled u-PA/l x 106 cells, saturation of binding
was achieved (Figure 5).
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Figure 4 Scatchard plot analysis of MAb '25I-98/6 binding to
CH3LC cells under untreated a, and PMA-treated conditions
(5 x 10-9M), 3 days b. In order to achieve binding of MAb 98/6,
CH3LC cells were preincubated with 10 ftg unlabelled u-PA/
1 x 106 cells for 1 h at room temperature prior to CRIA. Radio-
labelled MAb 98/6 was given in increasing amounts (from 1 x 105
to 3 x IO' c.p.m./l x 1O cells) for 1 h at room temperature.
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Figure 5 Competitive binding of unlabelled and '25l-labelled u-
PA on CH3LC cells. CH3LC cells (1 x 106) were incubated with
'251-u-PA (2 x 106 c.p.m.) together with increasing amounts of
unlabelled u-PA for 1 h at room temperature for the CRIA. Prior
to the assay, cells were incubated for 3 days in the absence (0)
or presence (A) of PMA (5 x 10-9M).
Discussion
In this study a CRIA was employed to determine cell surface
expression of endogenous u-PA on various human lung
cancer cell lines by using an u-PA specific monoclonal
antibody. Binding capacity of these cells for u-PA was
measured by applying exogenous, two-chain, active u-PA in
the CRIA. The cell lines could be distinguished into three
distinct groups by these parameters: (1) squamous cell car-
cinoma cell lines and - to a much greater extent - large cell
carcinoma cell lines expressed u-PA and were also able to
bind exogenous u-PA. (2) SCLC cell lines neither expressed
nor were able to bind u-PA and (3) mesothelioma cell lines
did not express endogenous, but could bind external u-PA.
These results are in keeping with and extend previous
observations (Heidtmann et al., 1989). In the earlier study
we found that NSCLC cell lines could produce u-PA along
with other components of the PA system, whereas SCLC and
mesothelioma cell lines were deficient in the synthesis of any
protein of the PA system. The finding that mesothelioma cell
lines are able to bind u-PA despite of their deficiencies for
the synthesis of PA may add a new parameter for the
differentiation of these lung tumours. It also demonstrates
that lung tumours ofdifferent origin produce the components
of the PA system and proteins of functional context in
various combinations which may ensue a different response
to signals of the microenvironment. For example by means of
free u-PA binding sites, mesothelioma cells could make use
of u-PA secreted by other cells. Since SCLC cell lines were
deficient of any constituent of the PA system and unrespon-
sive to treatment with PMA or growth factors, the high
malignancy of this tumour class may not be correlated to a
tumour-associated proteolytic activity of the PA system. It
may however well be that other proteinases or proteinases of
tumour-infiltrating normal cells play a role in the invasive
process of SCLC.
In an earlier study, Markus et al., 1980 investigated human
lung tumour tissue for its content of plasminogen activator.
No significant correlation was observed between the histo-
pathological types and grades of malignancy of squamous
cell carcinoma, adenocarcinoma and anaplastic carcinoma
and the overall content of u-PA in these tissues. The u-PA
producing cells were not defined in this study. Normal cells
present in tumour tissues, as for example macrophages
(Neumann & Sorge, 1983) and granulocytes (Granelli-Piper-
no et al., 1977), are known to produce large amounts of
u-PA. Indeed, recently it was reported that, when examining
tumour tissue, colon carcinoma cells did not produce m-
RNA for u-PA. Increased levels of u-PA-specific m-RNA
were however found in interstitial stromal cells at invasive
foci. Furthermore, some tumours cells were found to produce
m-RNA specific for the u-PA receptor (Pyke et al., 1991). It
may well be that tumour cells, deficient of PA production,
stimulate normal cells of the environment to increased pro-
teolytic activity. The expression of the u-PA receptor or
other, not yet defined binding structures for u-PA, may
enable these tumour cells to direct PA activity, present in the
microenvironment, to sites of invasive growth. If this were
the case, one would expect to find u-PA in close association
with tumour cells within tumour tissue. However, immuno-
histological examination of colon carcinoma tissue, using
specific MAb against u-PA, failed to detect u-PA located on
or close to the tumour cells (Gr0ndahl-Hansen et al., 1991).
Therefore, the function of u-PA binding sites on tumour
cells, deficient of the PA system, remains obscure at the
moment. It has been reported by several authors that pro-u-
PA binds to a specific surface receptor (Stoppelli et al., 1986;
Vassalli et al., 1985). The binding of active two-chain u-PA
to the cell surface is still a matter of controversy. Although
PA activity can be measured on cells, this does not unequiv-
ocally prove the binding of active u-PA to specific receptors.
Rapid conversion of receptor-bound pro-u-PA to active u-PA
may also occur. On the other hand, u-PA has been demon-
strated to form irreversible complexes with plasminogen
activator inhibitors, as e.g. PAI-I (Hebert & Baker, 1988)
and protease nexin (Howard & Knauer, 1987) which may
also be situated on the cell surface via a nexin-binding pro-
tein.
NSCLC cell lines had binding sites which were occupied
with endogenous u-PA. Since MAb 98/6 does not
differentiate between pro-u-PA and active u-PA, surface
staining by this antibody may indicate expression of both
forms of u-PA and, consequently specific u-PA receptors and
other proteins with binding capacity for u-PA. Mesothelioma
cells- had amounts of bindin sites (Figure 4) comparable to
those of squamous cell carcinoma cell lines (Figure 2), which
however additionally expressed endogenous u-PA. It may
therefore be that exogenous, active u-PA binds to a type of
structure, present on both cell types, which is not involved inUROKINASE ON HUMAN LUNG TUMOUR CELL LINES 57
binding of endogenous pro-u-PA. NSCLC cell lines had free
binding capacity which could be occupied by exogenous u-
PA.
Competition of unlabelled u-PA after consecutive addition
did not result in a replacement of labelled u-PA. This is in
contrast to earlier studies which found reversible binding of
pro-u-PA to its specific receptor with a low dissociation rate
(Stopelli et al., 1985). Further biochemical analysis of cell-
bound exogenous u-PA on lung tumour cells supports our
notion that active u-PA forms an irreversible complex with a
yet undefined protein (manuscript in preparation).
This study along with our previous ones concerning the
PA system of human lung tumour cell lines indicates the
possibility that the PA system is differently expressed in
various groups of lung tumours. For a comprehensive eval-
uation of the functional role of the PA systems, all com-
ponents of plasminogen activation and inhibtion as well as
surface binding sites and the influence of growth factors on
the entire system have to be taken into account. Further-
more, to understand in situ tumour-microenvironment inter-
actions, it will be necessary to transfer these insights to the
investigation of native tumour samples.
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